Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Feb 8;38(4):953–963. doi: 10.1161/ATVBAHA.118.310538

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 The Authors.

Arteriosclerosis, Thrombosis, and Vascular Biology is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited.

PMC Copyright notice

Figure 5. — Apolipoprotein A-I (apoA-I)–normalized cholesterol efflux capacity (CEC) discriminates patients with stable atherosclerotic disease and healthy subjects. Shown are individual data points, mean, and SD of baseline (A) total CEC, (B) apoA-I, (C) apoA-I–normalized CEC (calculated as the ratio of total CEC to apoA-I), and (D) high-density lipoprotein cholesterol (HDL-C) in healthy subjects participating in the phase 1 single ascending dose (SAD) study, phase 1 multiple ascending dose (MAD) study, the combined group of phase 1 SAD and MAD studies and the patients with stable atherosclerotic disease participating in the phase 2a study. Unpaired t test comparing the combined phase 1 SAD and MAD subjects vs phase 2a patients with stable atherosclerotic disease; ****P<0.001; **P<0.01; *P<0.05.